Payment overview · 2025
General Payments
$2,417.02
137 reported records · 22 companies
Healthcare provider profile · identity verified
Nancy V Morris, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LONDON, KY · NPI 1770543175
Verified facts
What the public records show
CMS Open Payments records show Nancy V Morris, M.D. received $2,417.02 in general payments during 2025 across 137 reported records.
AstraZeneca Pharmaceuticals LP accounted for 12.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Kerendia, Mounjaro, Ozempic, Rexulti, Rybelsus, Synthroid, Ubrelvy, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 391 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ubrelvy by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 194 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 662 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $308.95 | 12.8% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $272.61 | 11.3% | 18 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $272.16 | 11.3% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $261.98 | 10.8% | 14 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $249.74 | 10.3% | 20 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $174.34 | 7.2% | 12 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $133.88 | 5.5% | 6 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $114.06 | 4.7% | 7 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $106.68 | 4.4% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $90.24 | 3.7% | 6 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $58.10 | 2.4% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $56.16 | 2.3% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $52.65 | 2.2% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $51.92 | 2.1% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $48.69 | 2.0% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $44.61 | 1.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.16 | 1.2% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.25 | 0.9% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.53 | 0.8% | 1 | 2025 |
| Ferring Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.98 | 0.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.49 | 0.6% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $13.84 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,417.02 | 137 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $272.16 | 12 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $249.74 | 20 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $235.01 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $222.40 | 12 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $190.37 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $185.03 | 11 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $185.03 | 11 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $183.12 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $133.88 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $126.81 | 8 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $114.06 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $109.18 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $106.68 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $90.24 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $90.24 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $87.58 | 7 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $58.10 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $56.16 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $54.14 | 5 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $52.65 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $51.92 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $48.69 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $47.53 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $44.61 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $39.58 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $39.58 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $39.58 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $32.03 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.16 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $23.61 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.25 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $20.53 | 1 | 2025 |
Source payment records
|
|||||
| REBYOTA Normalized: rebyota |
Biological | Ferring Pharmaceuticals Inc. | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $13.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 662 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 104 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 188 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 164 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 62 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 391 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
391 | 99 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
25 | 17 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
116 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
104 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
58 | 13 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
194 | 46 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
188 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
77 | 17 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
164 | 42 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
62 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
662 | 100 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
33 | 33 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1782 | 383 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1529 | 354 |
| Amlodipine Besylate | Amlodipine Besylate | 952 | 237 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 735 | 188 |
| Pantoprazole Sodium | Pantoprazole Sodium | 676 | 157 |
| Eliquis | Apixaban | 662 | 100 |
| Gabapentin | Gabapentin | 640 | 105 |
| Metformin Hcl | Metformin Hcl | 501 | 109 |
| Lisinopril | Lisinopril | 477 | 106 |
| Tramadol Hcl | Tramadol Hcl | 476 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 414 | 112 |
| Metoprolol Succinate | Metoprolol Succinate | 401 | 106 |
| Synthroid | Levothyroxine Sodium | 391 | 99 |
| Clonazepam | Clonazepam | 390 | 61 |
| Escitalopram Oxalate | Escitalopram Oxalate | 387 | 89 |
| Potassium Chloride | Potassium Chloride | 381 | 68 |
| Pregabalin | Pregabalin | 368 | 48 |
| Furosemide | Furosemide | 367 | 97 |
| Omeprazole | Omeprazole | 366 | 94 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 363 | 83 |
| Metoprolol Tartrate | Metoprolol Tartrate | 346 | 78 |
| Carvedilol | Carvedilol | 338 | 78 |
| Montelukast Sodium | Montelukast Sodium | 319 | 83 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 304 | 74 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 300 | 73 |
| Donepezil Hcl | Donepezil Hcl | 281 | 25 |
| Memantine Hcl | Memantine Hcl | 281 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 274 | 62 |
| Allopurinol | Allopurinol | 273 | 63 |
| Glipizide Er | Glipizide | 272 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 272 | 73 |
| Celecoxib | Celecoxib | 269 | 57 |
| Sertraline Hcl | Sertraline Hcl | 260 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 243 | 59 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 242 | 49 |
| Ezetimibe | Ezetimibe | 230 | 58 |
| Zolpidem Tartrate | Zolpidem Tartrate | 230 | 33 |
| Raloxifene Hcl | Raloxifene Hcl | 227 | 45 |
| Alprazolam | Alprazolam | 226 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 223 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 214 | 79 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 211 | 48 |
| Quetiapine Fumarate | Quetiapine Fumarate | 201 | 34 |
| Jardiance | Empagliflozin | 194 | 46 |
| Trazodone Hcl | Trazodone Hcl | 194 | 36 |
| Mounjaro | Tirzepatide | 188 | 28 |
| Lorazepam | Lorazepam | 182 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 173 | 45 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 165 | 32 |
| Ozempic | Semaglutide | 164 | 42 |
| Meloxicam | Meloxicam | 162 | 51 |
| Metformin Hcl Er | Metformin Hcl | 160 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 159 | 36 |
| Famotidine | Famotidine | 152 | 33 |
| Lansoprazole | Lansoprazole | 149 | 30 |
| Chlorthalidone | Chlorthalidone | 147 | 34 |
| Dexlansoprazole Dr | Dexlansoprazole | 142 | 18 |
| Irbesartan | Irbesartan | 140 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 136 | 29 |
| Losartan Potassium | Losartan Potassium | 135 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 127 | 43 |
| Spironolactone | Spironolactone | 127 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 126 | 32 |
| Clonidine Hcl | Clonidine Hcl | 126 | 36 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 125 | 20 |
| Glipizide | Glipizide | 122 | 35 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 119 | 25 |
| Diazepam | Diazepam | 116 | 20 |
| Myrbetriq | Mirabegron | 116 | 15 |
| Ibuprofen | Ibuprofen | 115 | 27 |
| Ondansetron Hcl | Ondansetron Hcl | 113 | 47 |
| Hydralazine Hcl | Hydralazine Hcl | 110 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 109 | 15 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 108 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 105 | 20 |
| Farxiga | Dapagliflozin Propanediol | 104 | 20 |
| Valsartan | Valsartan | 103 | 29 |
| Buspirone Hcl | Buspirone Hcl | 102 | 24 |
| Bupropion Xl | Bupropion Hcl | 100 | 23 |
| Nebivolol Hcl | Nebivolol Hcl | 98 | 27 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 96 | 96 |
| Repatha Sureclick | Evolocumab | 93 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 31 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 91 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 89 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 87 | 22 |
| Simvastatin | Simvastatin | 87 | 27 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 86 | 22 |
| Baclofen | Baclofen | 85 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 84 | 19 |
| Sotalol | Sotalol Hcl | 84 | 17 |
| Atenolol | Atenolol | 83 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 77 | suppressed |
| Trulicity | Dulaglutide | 77 | 17 |
| Divalproex Sodium | Divalproex Sodium | 76 | suppressed |
| Fentanyl | Fentanyl | 75 | suppressed |
| Multaq | Dronedarone Hcl | 75 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 74 | suppressed |
| Clonidine | Clonidine | 71 | suppressed |
| Cefdinir | Cefdinir | 70 | 56 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 70 | 54 |
| Mirtazapine | Mirtazapine | 69 | suppressed |
| Fluconazole | Fluconazole | 68 | 45 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 68 | 20 |
| Colesevelam Hcl | Colesevelam Hcl | 67 | 16 |
| Estradiol | Estradiol | 66 | 21 |
| Levofloxacin | Levofloxacin | 66 | 44 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 65 | 19 |
| Ramipril | Ramipril | 62 | 18 |
| Rybelsus | Semaglutide | 62 | 14 |
| Lactulose | Lactulose | 60 | 23 |
| Azithromycin | Azithromycin | 59 | 53 |
| Spiriva Respimat | Tiotropium Bromide | 59 | 12 |
| Digoxin | Digoxin | 58 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 58 | 13 |
| Anastrozole | Anastrozole | 57 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 57 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 56 | 12 |
| Finasteride | Finasteride | 55 | 17 |
| Klor-Con M20 | Potassium Chloride | 55 | 17 |
| Nitroglycerin | Nitroglycerin | 55 | 35 |
| Amiodarone Hcl | Amiodarone Hcl | 54 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 13 |
| Mupirocin | Mupirocin | 51 | 22 |
| Diltiazem Hcl | Diltiazem Hcl | 50 | suppressed |
| Novolog Flexpen | Insulin Aspart | 50 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 11 |
| Carisoprodol | Carisoprodol | 47 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | 11 |
| Propranolol Hcl | Propranolol Hcl | 47 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 47 | 19 |
| Clobetasol Propionate | Clobetasol Propionate | 46 | 17 |
| Prednisone | Prednisone | 46 | 22 |
| Budesonide | Budesonide | 45 | suppressed |
| Entresto | Sacubitril/Valsartan | 44 | 11 |
| Ondansetron Odt | Ondansetron | 44 | 19 |
| Warfarin Sodium | Warfarin Sodium | 44 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 35 |
| Doxazosin Mesylate | Doxazosin Mesylate | 42 | 14 |
| Lidocaine | Lidocaine | 41 | suppressed |
| Nystatin | Nystatin | 41 | 24 |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | 12 |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 39 | 12 |
| Olanzapine | Olanzapine | 39 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 39 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 38 | suppressed |
| Methocarbamol | Methocarbamol | 38 | suppressed |
| Bumetanide | Bumetanide | 37 | 11 |
| Azelastine Hcl | Azelastine Hcl | 36 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 36 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 36 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 36 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 36 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 35 | suppressed |
| Linzess | Linaclotide | 35 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 23 |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Nabumetone | Nabumetone | 34 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 33 | 33 |
| Imipramine Hcl | Imipramine Hcl | 32 | suppressed |
| Methylprednisolone | Methylprednisolone | 32 | 27 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | 13 |
| Temazepam | Temazepam | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 31 | suppressed |
| Ranolazine Er | Ranolazine | 31 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 31 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 18 |
| Candesartan Cilexetil | Candesartan Cilexetil | 30 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 30 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 29 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Ketoconazole | Ketoconazole | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Galantamine Er | Galantamine Hbr | 27 | suppressed |
| Naproxen | Naproxen | 27 | 13 |
| Rexulti | Brexpiprazole | 27 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 26 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 26 | 11 |
| Latanoprost | Latanoprost | 26 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Glyburide | Glyburide | 25 | suppressed |
| Movantik | Naloxegol Oxalate | 25 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Prolia | Denosumab | 25 | 17 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 23 | 11 |
| Clotrimazole | Clotrimazole | 23 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Telmisartan | Telmisartan | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 22 | 22 |
| Cilostazol | Cilostazol | 22 | suppressed |
| Cyclosporine | Cyclosporine | 22 | suppressed |
| Dutasteride | Dutasteride | 22 | suppressed |
| Edarbi | Azilsartan Medoxomil | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 15 |
| Topiramate | Topiramate | 22 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Acetazolamide | Acetazolamide | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 20 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 20 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 20 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 20 | suppressed |
| Erythromycin | Erythromycin Base | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Praluent Pen | Alirocumab | 19 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 18 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 18 | suppressed |
| Nucynta | Tapentadol Hcl | 18 | suppressed |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Repatha Syringe | Evolocumab | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 17 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Kerendia | Finerenone | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 11 |
| Pitavastatin Calcium | Pitavastatin Calcium | 16 | suppressed |
| Armour Thyroid | Thyroid,pork | 15 | suppressed |
| Euthyrox | Levothyroxine Sodium | 15 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 15 | suppressed |
| Invokana | Canagliflozin | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Trulance | Plecanatide | 15 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Xifaxan | Rifaximin | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Asa-Butalb-Caffeine-Codeine | Codeine/Butalbital/Asa/Caffein | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Dexilant | Dexlansoprazole | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Droxidopa | Droxidopa | 13 | suppressed |
| Hysingla Er | Hydrocodone Bitartrate | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Ubrelvy | Ubrogepant | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Dofetilide | Dofetilide | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,417.02 · 137 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AUSTEDO XR, Auvelity, BREZTRI, CAPVAXIVE, COMIRNATY, ELIQUIS, FARXIGA, GEMTESA, IBSRELA, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PREVNAR 20, QULIPTA, REBYOTA, REPATHA, REXULTI, Rybelsus, SPRAVATO, SYNTHROID, UBRELVY, VOQUEZNA, VOWST, VRAYLAR, Veozah, Wegovy, XIFAXAN, XYOSTED, ZAVZPRET, ZEPBOUND | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error